Cross John Harry III 4

4 · Sonnet BioTherapeutics Holdings, Inc. · Filed Feb 17, 2023

Insider Transaction Report

Form 4
Period: 2023-02-06
Cross John Harry III
Chief Financial Officer
Transactions
  • Tax Payment

    Common Stock

    2023-02-06$1.06/sh1,960$2,07823,927 total
Footnotes (1)
  • [F1]Includes unvested restricted stock units.

Documents

1 file
  • 4
    ownership.xmlPrimary